HEM — Hemostemix Cashflow Statement
0.000.00%
- CA$14.10m
- CA$18.81m
Annual cashflow statement for Hemostemix, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.87 | -7.77 | -6.29 | -5.24 | -2.5 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.438 | 2.62 | 0.247 | 0.351 | 0.527 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.03 | -0.826 | 2.82 | -1.71 | 0.555 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -3.4 | -5.98 | -3.48 | -6.1 | -1.42 |
Capital Expenditures | -0.006 | 0 | — | — | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | 0.171 | 0 | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.006 | 0 | 0.171 | 0 | — |
Financing Cash Flow Items | — | -0.707 | -0.064 | -0.202 | -0.078 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.96 | 6.21 | 3.27 | 6.02 | 1.44 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.45 | 0.234 | -0.039 | -0.084 | 0.02 |